
Sign up to save your podcasts
Or


ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.
Links to studies discussed in this episode (subscription may be required):
BEAT-meso: Link
Checkmate 816 4 year update: Link
MIST5: Link
ctDNA-Lung-DETECT: Link
BEAT-SC: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
By Michael Fernando and Josh Hurwitz4.5
44 ratings
ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.
Links to studies discussed in this episode (subscription may be required):
BEAT-meso: Link
Checkmate 816 4 year update: Link
MIST5: Link
ctDNA-Lung-DETECT: Link
BEAT-SC: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.

320 Listeners

501 Listeners

122 Listeners

134 Listeners

3,387 Listeners

20 Listeners

202 Listeners

46 Listeners

8,006 Listeners

520 Listeners

61 Listeners

4 Listeners

195 Listeners

196 Listeners

46 Listeners